title: Reduction of postoperative immunosuppression with ranitidine in patients with cancer of the stomach or large bowel.
abstract: OBJECTIVE
  To assess the effect of ranitidine on cellular immune response (and postoperative infective morbidity) in a homogeneous group of patients.
  
  
  METHODS
  Prospective randomized controlled trial.
  
  
  METHODS
  University hospital, Italy.
  
  
  METHODS
  42 patients about to undergo curative resection for carcinoma of the colon, rectum, or stomach.
  
  
  METHODS
  Cell mediated immunity was tested 3 days before, and 4 days after, operation by reactions to 7 recall antigens (Multitest, Merieux). 21 patients were randomly allocated to receive ranitidine 100 mg twice daily intravenously from the day before operation until the third postoperative day.
  
  
  METHODS
  Comparison of the number of reactive patients and number of positive antigens before and after operation; and correlation between reactivity and incidence of postoperative infective complications.
  
  
  RESULTS
  The median (range) skin test scores preoperatively were: ranitidine group 8.5 (0-17), and control group 10 (0-19). The postoperative figures were 7 (0-28) and 4.5 (0-15.5) respectively. The corresponding numbers of positive antigens were 1 (0-4) and 3 (0-4) compared with 1 (0-5) and 1 (0-3). The changes in the scores did not seem to be influenced by blood transfusion, serum albumin concentration, age of the patient, or type of tumour. Two patients died in the ranitidine group (pulmonary embulus, n = 1, necrotising pancreatitis, n = 1) and there were 4 wound infections. There were no deaths in the control group, one intra-abdominal abscess, and 8 wound infections. Median hospital stay was similar, 10 (8-16) in the ranitidine group, and 11 (5-20) in the control group.
  
  
  CONCLUSIONS
  Ranitidine had a beneficial effect on cell-mediated immunity as it seemed to prevent the usual postoperative reduction in reactivity, but there was no significant difference in the incidence of infective complications though it was lower in the ranitidine group.
authors.affiliation: Institute of Clinica Chirurgica, Università di Bari, Italy.
authors.forename: D F
authors.initials: DF
authors.lastname: Altomare
authors.forename: L
authors.initials: L
authors.lastname: Lupo
authors.forename: O C
authors.initials: OC
authors.lastname: Pannarale
authors.forename: M G
authors.initials: MG
authors.lastname: Di Corcia
authors.forename: V
authors.initials: V
authors.lastname: Memeo
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003082:Colectomy / Q000379:methods; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000601:surgery*; D005260:Female; D005743:Gastrectomy / Q000379:methods; D006801:Humans; D007109:Immunity / Q000187:drug effects; D007165:Immunosuppression Therapy / Q000379:methods*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D011184:Postoperative Period; D011446:Prospective Studies; D011899:Ranitidine / Q000627:therapeutic use*; D012004:Rectal Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000601:surgery*; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000601:surgery*; D013530:Surgical Wound Infection
chemical_list: D011899:Ranitidine